MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
An open-label, multicenter, phase 1, dose escalation study of MLN4924 in adult patients with
acute myelogenous leukemia (AML), high-grade myelodysplastic syndrome (MDS). The patient
population will consist of adults previously diagnosed with AML including high-grade MDS for
which standard curative, life-prolonging treatment does not exist or is no longer effective.